Forrest Nollaig purchased $66K of AMRZ

Amrize (SWX:AMRZ) appointed Mario Gross as President of its Building Envelope division following Jake Gosa's resignation. The company's shares trade at CHF32.07, down 15.3% over the past month and 28.5% over the last quarter. Analysts suggest a fair value of CHF46.66, citing potential earnings power and margin expansion from the ASPIRE synergy program. The P/E ratio is 17.3x, compared to an estimated fair ratio of 30.5x and a peer average of 48.6x.

Wells Fargo downgraded Amrize (AMRZ) to Equal Weight, lowering its price target to $44 from $55. The firm cited a cautious 2027 outlook due to reduced government spending and higher interest rates, expecting organic volume declines. This follows similar downgrades in the construction materials sector.

Wells Fargo's Timna Tanners downgraded Vulcan Materials (VMC) to Underweight, cutting the target to $254. BMO's John McNulty downgraded Westlake (WLK) to Market Perform, reducing the target to $82. Tanners also downgraded Amrize (AMRZ) and Eagle Materials (EXP), lowering their targets to $44 and $196, respectively.

Jenisch Jan Philipp (Chairman & CEO) purchased 26,000 shares of Amrize Ltd (AMRZ) at an average of $42.46 ($42.37–$42.53, $1.10M total) across 3 trades on 2026-09-02.

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.